Clinical trial Recruiting at 1 site Observational

Healthcare European Amyloidosis Registry

Official title: Registre HEAR, Healthcare European Amyloidosis Registry

Run by Saving Lives Matters · NCT05101304 · Data updated 2026-11-12

This study is collecting information from patients with cardiac amyloidosis to better understand how the disease affects them over time without changing their treatment.

More Cardiac Amyloidosis trials

Quick facts

Study typeObservational
SexAll
Enrollment5000 (estimated)
SponsorSaving Lives Matters
Research network
Locations1 site (Créteil)
StatusRecruiting
StartedJune 29, 2021
Main results expectedJune 30, 2027
Study endsDecember 31, 2027
Registry record updatedNovember 1, 2021
Trial IDNCT05101304 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults with a confirmed or suspected diagnosis of cardiac amyloidosis.

Probably not a fit

Patients who have expressed refusal to participate or are involved in other interventional studies may not benefit from this registry.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect data on patients with confirmed or suspected cardiac amyloidosis without interfering with their management. It includes three cohorts: a retrospective cohort of deceased patients, a retro-prospective cohort of patients already diagnosed, and a prospective cohort of patients referred for suspected amyloidosis. The study will gather information related to patient management throughout their follow-up, allowing for a comprehensive understanding of the disease's impact and progression.

Why it matters

Potential benefit: If successful, this registry could enhance the understanding of cardiac amyloidosis and improve patient management strategies.

How similar studies have gone: Other observational studies have successfully gathered valuable data on rare diseases, suggesting that this approach could yield meaningful insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
INCLUSION CRITERIA

1. Patients must meet all of the following inclusion criteria to be included in the study:

   * Major patient
   * Protected adult patient (guardianship or curatorship)
2. Prospective Cohort:

   Patients referred or who have been referred to the participating centre for suspected amyloidosis.

   Patient who signed the patient information "Prospective Cohort" note
3. Retro-prospective Cohort:

   Patient already followed in the center with a confirmed diagnosis of amyloidosis Patient who signed the "retro-prospective cohort" patient information note
4. Retrospective cohort:

Deceased patients followed in the center with a confirmed diagnosis of amyloidosis

Study participants will not be compensated for their participation

EXCLUSION CRITERIA The patient has expressed his/her refusal to participate Participation in another study, even an interventional one, is not a criterion for non-inclusion.

Where it's running

  • Hôpital Henri Mondor
    Créteil, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.